My research focus is on the clinical treatment of patients with non-malignant hematologic disease. In particular, we have provided comprehensive care to a large cohort of adult patients with sickle cell disease as part of a funded Adult Hemoglobinopathy Treatment Center and have participated in several investigator-initiated and sponsored studies. For the treatment of sickle cell disease, one current focus is in further understanding the issues in transitioning from pediatric to adult care. Another focus is in the understanding and treatment of iron overload disorders with oral iron chelators. In addition to iron overload, I also have a longstanding interest in the diagnosis and treatment of iron deficiency anemia including the use of IV iron agents.
The second major clinical focus is the treatment of immune-mediated hematologic disease, most notably including ITP and TTP, with both newer regimens of immunosuppression as well as small molecules. We have participated in several clinical trials evaluating new approaches to the treatment of these diseases.
Lastly, my focus has been on the diagnosis and treatment of bleeding and thromboembolic disorders, including the participation in several multicenter studies for the treatment of venous thromboembolism. We have also recently established a Comprehensive Hemophilia Treatment Center including a multidisciplinary approach and are expanding our role in the hemophilia community.
| 1973-1977 | B.S., University of Notre Dame, Notre Dame, IN |
| 1977-1981 | M.D., St. Louis University School of Medicine, St. Louis, MO |
| 1981-1984 | Resident in Internal Medicine, Department of Medicine, University of Illinois School of Medicine, Chicago, IL |
| 1984-1986 | Fellow in Hematology, Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA |
| 1986-1990 | Post-doctoral Research Fellow, Division of Hematology-Oncology, Washington University School of Medicine, St. Louis, MO |
| 1990-1998 | Assistant Professor, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, MO |
| 1994-present | Medical Director, Wohl Hematology Laboratory |
| 1996-present | Associate Member, Alvin J. Siteman Cancer Center |
| 1998-present | Associate Professor of Medicine and Pathology & Immunology, Washington University School of Medicine, St. Louis, MO |
| 1990-present | Barnes-Jewish Hospital Medical Staff |
| 2000-present | Medical Staff Association, Barnes-Jewish Hospital |
| 2005-2007 | Vice Chair of the Executive Committee of the Faculty Council, Washington University School of Medicine |
| 2007-present | Transfusion Committee, Barnes-Jewish Hospital |
| 2010-present | Associate Director, Hematology-Oncology Fellowship Program |
| 1984 | Diplomate of the American Board of Internal Medicine |
| 1987 | Diplomate of the American Board in Medical Oncology |
| 1988 | Diplomate of the American Board in Hematology |
| 1987-1989 | Fellow of the American Heart Association, Missouri Affiliate |
| 1990 | European Patent Number 90870188.1 “Modified Heparin Cofactor II”; Inventors: DM Tollefsen, VM Derechin, MA Blinder |
| 1992 | U.S. Patent Number 5,102,995 “DNA Encoding Modified Heparin Cofactor II”; Inventors: DM Tollefsen, VM Derechin, MA Blinder |
| 1992 | U.S. Patent Number 5,118,793 “Modified Heparin Cofactor II ”; Inventors: DM Tollefsen, VM Derechin, and MA Blinder |
| 1995 | Outstanding Teacher for the 1994-95 Academic Year, Department of Internal Medicine, Washington University School of Medicine |
| 1999 | Dr. Neville Grant Award for Clinical Excellence |
| 2001-2011 | Listed in Best Doctors in America |
| 2001-2011 | Listed in Castle Connolly America’s Top Doctors |
| 2004-present | Missouri Genetic Disease Advisory Committee, Appointed by Governor Bob Holden; Reappointed by Governor Matt Blunt 2006; Reappointed by Governor Jay Nixon 2010 |
| 2008-present | Chairman, Sickle Cell Anemia Standing Committee, State of Missouri, Department of Health and Senior Services |
| 1992 | American Society of Hematology |
| 1993 | American College of Physicians, Member |
| 1995 | Academy of Clinical Laboratory Physicians and Scientists |
| 2008-2011 | Data and Safety Monitoring Board, National Institute of Neurologic Disorders and Stroke Desferoxamine in Intracranial Hemorrhage Trial |
| 2011-present | Chairman, Safety Monitoring Committee, National Heart, Lung and Blood Institute (NHLBI), Safety to Reduce Iron Deficiency (STRIDE) Study |
| 2011-present | Panel Member, NCCN Guidelines - Cancer and Chemotherapy-Induced Anemia |